SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                               __________________

                                   FORM 8-K/A

              CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


       DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) September 19, 2002


                           UNIGENE LABORATORIES, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)


        DELAWARE                         0-16005                 22-2328609
(STATE OR OTHER JURISDICTION           (COMMISSION            (I.R.S. EMPLOYER
    OF INCORPORATION)                  FILE NUMBER)          IDENTIFICATION NO.)

                              110 LITTLE FALLS ROAD
                           FAIRFIELD, NEW JERSEY 07004
               (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE            (973) 882-0860





ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT

     On August 30, 2002, Unigene Laboratories,  Inc. (the "Company"), decided to
appoint Grant Thornton LLP as its new independent  auditor.  The Company's Audit
Committee  and Board of Directors  participated  in and approved the decision to
appoint  Grant  Thornton.  Grant  Thornton  was engaged by the Company to be its
independent auditor on September 19, 2002.

     During the two most recent  fiscal  years ended  December 31, 2001 and 2000
and through the date of this Form 8-K/A,  neither the Company, nor anyone on its
behalf,  has consulted with Grant Thornton  regarding  either the application of
accounting principles to a specified transaction,  either completed or proposed,
or the type of audit opinion that might be rendered on the  Company's  financial
statements,   or  any  matters  or  reportable   events   described  under  Item
304(a)(2)(i) and (ii) of Regulation S-K.





                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                     UNIGENE LABORATORIES, INC.

                                                     /s/  Warren P. Levy
                                                     ---------------------------
Date:   September 19, 2002                           By: Warren P. Levy
                                                     President
                                                     (Chief Executive Officer)